Co-Diagnostics, Inc. (CODX): Price and Financial Metrics


Co-Diagnostics, Inc. (CODX): $4.99

0.36 (+7.78%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CODX POWR Grades


  • CODX scores best on the Value dimension, with a Value rank ahead of 99.53% of US stocks.
  • The strongest trend for CODX is in Growth, which has been heading up over the past 179 days.
  • CODX ranks lowest in Stability; there it ranks in the 3rd percentile.

CODX Stock Summary

  • With a price/earnings ratio of 6.05, Co-Diagnostics Inc P/E ratio is greater than that of about only 10.27% of stocks in our set with positive earnings.
  • The ratio of debt to operating expenses for Co-Diagnostics Inc is higher than it is for about merely 0.5% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at 1.1 for Co-Diagnostics Inc; that's greater than it is for only 8.36% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Co-Diagnostics Inc, a group of peers worth examining would be KN, FUV, ACER, AFIB, and VRCA.
  • CODX's SEC filings can be seen here. And to visit Co-Diagnostics Inc's official web site, go to www.codiagnostics.com.

CODX Valuation Summary

  • CODX's price/earnings ratio is 6.7; this is 81.64% lower than that of the median Healthcare stock.
  • Over the past 50 months, CODX's price/sales ratio has gone NA NA.
  • CODX's price/earnings ratio has moved up 40.4 over the prior 50 months.

Below are key valuation metrics over time for CODX.

Stock Date P/S P/B P/E EV/EBIT
CODX 2021-08-31 3.2 3.6 6.7 4.8
CODX 2021-08-30 3.2 3.6 6.8 4.8
CODX 2021-08-27 3.3 3.6 6.8 4.8
CODX 2021-08-26 3.3 3.6 6.9 4.9
CODX 2021-08-25 3.3 3.6 6.8 4.9
CODX 2021-08-24 3.2 3.6 6.8 4.8

CODX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • CODX has a Quality Grade of B, ranking ahead of 88% of graded US stocks.
  • CODX's asset turnover comes in at 1.285 -- ranking 10th of 186 Medical Equipment stocks.
  • ALGN, IART, and XENT are the stocks whose asset turnover ratios are most correlated with CODX.

The table below shows CODX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.285 0.835 2.189
2021-03-31 1.529 0.792 2.398
2020-12-31 1.631 0.777 2.360
2020-09-30 1.671 0.740 2.026
2020-06-30 1.636 0.746 2.230
2020-06-30 1.636 0.654 1.725

CODX Price Target

For more insight on analysts targets of CODX, see our CODX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $22.50 Average Broker Recommendation 1.67 (Moderate Buy)

CODX Stock Price Chart Interactive Chart >

Price chart for CODX

CODX Price/Volume Stats

Current price $4.99 52-week high $11.82
Prev. close $4.63 52-week low $3.66
Day low $4.65 Volume 277,406
Day high $5.18 Avg. volume 417,233
50-day MA $5.25 Dividend yield N/A
200-day MA $7.71 Market Cap 169.60M

Co-Diagnostics, Inc. (CODX) Company Bio


Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was founded in 2013 and is headquartered in Salt Lake City, Utah.


CODX Latest News Stream


Event/Time News Detail
Loading, please wait...

CODX Latest Social Stream


Loading social stream, please wait...

View Full CODX Social Stream

Latest CODX News From Around the Web

Below are the latest news stories about Co-Diagnostics Inc that investors may wish to consider to help them evaluate CODX as an investment opportunity.

Co-Diagnostics, Inc. to Sponsor and Present at Molecular Med Tri-Con 2022

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be a premium sponsor of the upcoming Molecular Med Tri-Con held February 21-23, 2022 in San Diego, CA, which will also include a presentation by representatives of the Company and its newly-acquired subsidiary.

Yahoo | February 17, 2022

Co-Diagnostics, Inc. to Host Booth at Life Sciences Day on the Hill on February 16 at the Utah State Capital

Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth at the upcoming Life Sciences Day on the Hill on February 16, 2022, at the Utah State Capital Building.

Yahoo | February 10, 2022

Wall Street Analysts Are Bullish on Top Healthcare Picks

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Co-Diagnostics (CODX – Research Report), Tempest Therapeutics (TPST – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments. Co-Diagnostics (CODX) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Co-Diagnostics, with a price target of $15.00. The company's shares closed last Thursday at $6.83, close to its 52-week low of $6.48. According to TipRanks.com, Chen is a 5-star analyst with an average return of -18.8% and a 23.8% success rate.

Catie Powers on TipRanks | February 4, 2022

Co-Diagnostics announces approval for Hep B test in India

Co-Diagnostics (NASDAQ:CODX) announced its joint venture in India, CoSara Diagnostics, received clearance from the regulatory authorities to manufacture and sell SARAQ Hepatitis B (HBV) Viral Load Kit there as an in vitro diagnostic ("IVD"). The real-time PCR test for HBV is based on Co-Diagnostics’ (CODX) CoPrimer technology, and it will...

Seeking Alpha | February 3, 2022

Co-Diagnostics announces approval for Hep B test in India (NASDAQ:CODX)

Co-Diagnostics (CODX) announced its joint venture in India, CoSara Diagnostics, received clearance from the regulatory authorities to manufacture and sell SARAQ Hepatitis B ((HBV))

Seeking Alpha | February 3, 2022

Read More 'CODX' Stories Here

CODX Price Returns

1-mo 10.15%
3-mo -12.91%
6-mo -47.80%
1-year -39.07%
3-year 497.53%
5-year N/A
YTD -44.12%
2021 -3.98%
2020 938.87%
2019 -39.92%
2018 -43.56%
2017 N/A

Continue Researching CODX

Want to see what other sources are saying about Co-Diagnostics Inc's financials and stock price? Try the links below:

Co-Diagnostics Inc (CODX) Stock Price | Nasdaq
Co-Diagnostics Inc (CODX) Stock Quote, History and News - Yahoo Finance
Co-Diagnostics Inc (CODX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.529 seconds.